FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a pharmaceutical lyophilised preparation of botulinum toxin. The pharmaceutical lyophilised preparation contains: botulinum toxin, Polysorbate, and methionine; Polysorbate is taken in an amount of 0.01 to 2 mg per 100 units of botulinum toxin, and methionine is taken in an amount of 0.01 to 10 mg per 100 units of botulinum toxin; and one or more components specified in a group consisting of sugar in an amount of 0.1 to 50 mg per 100 units of botulinum toxin, sugar alcohol in an amount of 0.1 to 50 mg per 100 units of botulinum toxin and an ionic compound in an amount of 0.1 to 10 mg per 100 units of botulinum toxin.
EFFECT: above pharmaceutical lyophilized preparation of botulinum toxin is storage-table and can be stored for a long period of time at a temperature higher than normal.
7 cl, 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LYOPHILISED PREPARATION OF BOTULINUM TOXIN | 2012 |
|
RU2640922C1 |
| LIQUID COMPOSITION STABILIZING BOTULINUM TOXIN | 2019 |
|
RU2812790C2 |
| COMPOSITION FOR PROTEIN PHARMACEUTICAL PREPARATION WITH NO ADDED HUMAN SERUM ALBUMIN (HSA) | 2004 |
|
RU2491927C2 |
| LIQUID FORMULATIONS FOR LONG-ACTING ERYTHROPOIETIN CONJUGATE | 2011 |
|
RU2682720C2 |
| LIQUID PHARMACEUTICAL COMPOSITION OF BOTULINUM TOXIN | 2008 |
|
RU2440825C2 |
| AQUEOUS SOLUTION OF FACTOR VIII AT DECREASED OXYGEN CONCENTRATION | 1994 |
|
RU2142290C1 |
| LIQUID FORMULATION OF LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2013 |
|
RU2671576C2 |
| FLUID FORMULATION OF FOLLICLE-STIMULATING HORMONE | 2011 |
|
RU2553375C2 |
| COMPOSITION FOR PROTEIN PHARMACEUTICAL MEDICATION WITHOUT ADDITION OF HUMAN SERUM ALBUMEN (HSA) | 2004 |
|
RU2354366C2 |
| FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | 2013 |
|
RU2683861C2 |
